Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOICE: COVID-19 vaccination in patients with cancer
NL-OMON52037Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of elasomeran in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by University Medical Center Groningen. Primary endpoint: Primary immunogenicity endpoint. Started Jan 2021; status: recruiting.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON52037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52037.